Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07180901

Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer

Delays between surgery and the initiation of post-operative radiotherapy (S-PORT) in head and neck cancer (HNC) patients are prevalent and associated with worse oncologic outcomes. This pilot study evaluates whether a proactive, automated care coordination system (PRONTO-HN) can improve adherence to recommended S-PORT intervals of ≤42 days at the Centre hospitalier de l'Université de Montréal (CHUM).

The study is a single-center, quasi-experimental, interrupted time-series design with two phases. Group A (control) includes patients treated before the intervention (using a prospectively maintained database from August 2024 to August 2025). Group B (intervention) includes patients treated with the new coordination system from September 2025 to September 2026.

The intervention includes automated alerts, multidisciplinary task coordination, and risk stratification based on a predictive model developed and published by our team. This model uses only pre-operative data to estimate the likelihood that a patient will require adjuvant therapy after surgery, stratifying patients into high- and low-risk categories. High-risk patients receive intensified coordination protocols, including early oncology and dental consultations and shorter target times for pathology results.

Primary objective: Reduce the proportion of patients with S-PORT > 42 days. Secondary/tertiary objectives: Reduce mean S-PORT time. Evaluate impacts on overall, locoregional, and disease-free survival in a 2- and 3-year follow up study.

Patients are identified at the time the operating room request is submitted. Demographic, clinical, and oncologic data are collected and stored securely in REDCap. As the intervention is administrative in nature and does not modify patient care, consent is waived.

Statistical analysis will evaluate the intervention's effect and identify predictors of delays. A sample of 38 patients per group provides adequate power to detect a drop in S-PORT > 42 days from 80% to 50%.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, H2X 0C1, Canada

Location status: Recruiting

Location contact

Apostolos Christopoulos, MD, MSc

CONTACT

[email protected]

514-625-7360‬

Houda Bahig, MD, PhD

CONTACT

[email protected]

514-690-8546‬

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All adult patients (age 18 or older).
  • Pathologically confirmed oral cavity or laryngeal squamous cell carcinoma.
  • Diagnosed from July 2024 to September 2026.
  • With planned primary intention surgical resection.
  • With or without adjuvant therapy.
  • Treated at the Centre Hospitalier de l'Université de Montréal.

Exclusion criteria

  • Patients who do not end up receiving surgery.
  • S-PORT > 180 days

Treatment and study plan

Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)

Other

Post-implementation of PRONTO-HN system: 1. Pre-operative risk stratification of requiring adjuvant therapy using our predictive model, applied at tumor board. Patients stratified as fast-track vs normal-track. 2. High-risk patients receive intensive preoperative and postoperative coordination. Low-risk patients are monitored but escalated rapidly if adverse pathology is detected. This includes: - pre-operative dental consultation for fast-track - pre-operative oncology consultation for fast-track with high-risk features - target pathology results 14 days post-operatively for fast-track 3. Automated reminders and target dates sent to members of the multidisciplinary team.

Primary outcomes

  1. Surgery to post-operative radiotherapy time (S-PORT)

    Time frame: Day 1 of radiotherapy (assessed up to 12 weeks post-operatively)

    Number of days between surgery and start of radiotherapy (adjuvant)

Secondary outcomes

  1. Overall survival

    Time frame: From date of surgery until the date of date from any cause (assessed up to 60 months)

    Event: Death (of any cause) Censor: Alive at last follow-up

  2. Locoregional Survival

    Time frame: From date of surgery until the date of locoregional recurrence or death, whichever came first (assessed up to 60 months)

    Event: Locoregional recurrence (primary site or cervical node) or death Censored: Alive and without locoregional recurrence at last follow-up

  3. Distant metastasis-free survival

    Time frame: The time from surgery to event. From date of surgery until the date of distant metastasis or death, whichever came first (assessed up to 60 months)

    Event: Distant metastasis or death Censored: Alive and without distant metastasis at last follow-up

  4. Recurrence-Free Survival

    Time frame: From date of surgery until the date of locoregional recurrence or distant metastasis, whichever came first (assessed up to 60 months)

    Event: Any recurrence (local, regional, or distant) Censored: Recurrence-free at last follow-up. Death without recurrence also censored.

  5. Disease-Free Survival

    Time frame: From date of surgery until the date of locoregional recurrence or distant metastasis or death, whichever came first (assessed up to 60 months)

    Event: Recurrence (any site) or death Censored: Alive and disease-free at last follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Apostolos Christopoulos, MD, MSc

CONTACT

[email protected]

‭+1 (514) 625-7360‬

Gabriel S Dayan, MD

CONTACT

[email protected]

5147782303

Sponsors and collaborators

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Other

Registry information

Official study title

Proactive Risk-based Optimization & Notifications for Treatment & Outcomes (PRONTO) in Head & Neck Cancer: A Strategy to Reduce Delays From Surgery to Post-Operative Adjuvant Therapy in Head and Neck Cancer

Acronym: PRONTO-HN

Important dates

Study start
2025
Primary completion
2026
Study completion
2029
First posted
Sep 18, 2025
Registry last updated
Sep 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.